Cilengitide affects tumor compartment, vascularization and microenvironment in experimental bone metastases as shown by longitudinal 18F-FDG PET and gene expression analysis-Reference-Cited by-同舟云学术

Cilengitide affects tumor compartment, vascularization and microenvironment in experimental bone metastases as shown by longitudinal 18F-FDG PET and gene expression analysis

Published:2012-12-11 Issue:4 Volume:139 Page:573-583
ISSN:0171-5216
Container-title:Journal of Cancer Research and Clinical Oncology
language:en
Short-container-title:J Cancer Res Clin Oncol

Author:

Bretschi Maren,Cheng Caixia,Witt Hendrik,Dimitrakopoulou-Strauss Antonia,Strauss Ludwig G.,Semmler Wolfhard,Bäuerle Tobias

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00432-012-1360-6.pdf

Reference33 articles.

1. Alghisi GC, Ponsonnet L, Ruegg C (2009) The integrin antagonist cilengitide activates αvβ3, disrupts VE-cadherin localization at cell junctions and enhances permeability in endothelial cells. PLoS ONE 4:e4449

2. Bäuerle T, Adwan H, Kiessling F, Hilbig H, Armbruster FP, Berger MR (2005) Characterization of a rat model with site-specific bone metastasis induced by MDA-MB-231 breast cancer cells and its application to the effects of an antibody against bone sialoprotein. Int J Cancer 115:177–186

3. Bäuerle T, Merz M, Komljenovic D, Zwick S, Semmler W (2010) Drug-induced vessel remodeling in bone metastases as assessed by dynamic contrast enhanced magnetic resonance imaging and vessel size imaging: a longitudinal in vivo study. Clin Cancer Res 16:3215–3225

4. Bäuerle T, Komljenovic D, Merz M, Berger MR, Goodman SL, Semmler W (2011) Cilengitide inhibits progression of experimental breast cancer bone metastases as imaged non-invasively using VCT, MRI and DCE-MRI in a longitudinal in vivo study. Int J Cancer 128:2453–2462

5. Beekman KW, Colevas AD, Cooney K, Dipaola R, Dunn RL, Gross M, Keller ET, Pienta KJ, Ryan CJ, Smith D, Hussain M (2006) Phase II evaluations of cilengitide in asymptomatic patients with androgen-independent prostate cancer: scientific rationale and study design. Clin Genitourin Cancer 4:299–302

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Small Molecule–Drug Conjugate (SMDC) Consisting of a Modified Camptothecin Payload Linked to an αVß3 Binder for the Treatment of Multiple Cancer Types;Cancers;2022-01-13

2. Dual integrin αvβ3 and αvβ5 blockade attenuates cardiac dysfunction by reducing fibrosis in a rat model of doxorubicin-induced cardiomyopathy;Scandinavian Cardiovascular Journal;2021-07-23

3. Targeting Intercellular Communication in the Bone Microenvironment to Prevent Disseminated Tumor Cell Escape from Dormancy and Bone Metastatic Tumor Growth;International Journal of Molecular Sciences;2021-03-13

4. Inhibition of αvβ3 integrin impairs adhesion and uptake of tumor-derived small extracellular vesicles;Cell Communication and Signaling;2020-09-25

5. EDIL3 promotes epithelial–mesenchymal transition and paclitaxel resistance through its interaction with integrin αVβ3 in cancer cells;Cell Death Discovery;2020-09-16